Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Study Design: This ia a Phase II study.
Subjects: Patients with chemotherapy naive epithelial ovarian cancer; or fallopian, primary
peritoneal and papillary serous mullerian tumors will be recruited.
Carboplatin and Taxol (paclitaxel) will be administered concurrently with bevacizumab after
surgery for 6-8 cycles every 21 (q21) days. Bevacizumab will be omitted in the first cycle,
immediately post-operatively. This will be followed by one year of bevacizumab q21.
Outcomes: Outcomes include toxicity, response rate, and progression free survival.